Becton Dickinson and Company Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: November 5, 2026 results vs estimates
Becton Dickinson and Company Forecast
Becton Dickinson and Company short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 22.0% a year, a typical one-standard-deviation range is 192.19–204.49 over a week, 185.73–210.95 over a month and 154.67–242.01 over a year. (Signals as of 1 Nov 2026.)
Becton Dickinson and Company Price Chart
Becton Dickinson and Company Factors
YoY +36.1%
YoY +3.8%
YoY +1.3%
YoY −3.3%
YoY +0.1%
YoY +10.5%
YoY −26.5%
YoY +0.7%
YoY −1.8%
YoY −16.0%
YoY −14.2%
YoY −21.0%
YoY −13.2%
YoY +6.6%
YoY −12.8%
YoY −14.3%
Becton Dickinson and Company fundamentals: income statement, balance sheet & cash flow
Becton Dickinson and Company reported revenue of $19.46bn and net income of $1.15bn in FY2026, the year ended 30 September 2026 — revenue down 10.9% and net income down 31.7% on the prior year. Free cash flow was $2.69bn. These figures are as reported in the filings, not restated: 42 fiscal years and 165 quarters of history, back to September 1985. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD billions | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | 30 Sep 2026 | 30 Sep 2025 | 30 Sep 2024 | 30 Sep 2023 | 30 Sep 2022 |
| Revenue | 19.46 | 21.84 | 20.18 | 19.37 | 18.87 |
| Cost of revenue | 10.24 | 11.92 | 11.05 | 11.20 | 10.39 |
| Gross profit | 9.21 | 9.92 | 9.13 | 8.17 | 8.48 |
| Research & development | 0.99 | 1.26 | 1.19 | 1.24 | 1.26 |
| Operating income | 2.26 | 2.58 | 2.40 | 2.11 | 2.28 |
| EBITDA | 4.61 | 4.96 | 4.82 | 4.40 | 4.41 |
| Interest expense | 0.56 | 0.61 | 0.53 | 0.45 | 0.40 |
| Pre-tax income | 1.81 | 1.88 | 2.01 | 1.66 | 1.78 |
| Income tax | 0.39 | 0.20 | 0.30 | 0.13 | 0.15 |
| Net income | 1.15 | 1.68 | 1.71 | 1.48 | 1.78 |
Download Becton Dickinson and Company fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.BDX.NYSE&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Becton Dickinson and Company
Explore MacroFinance macro & markets research and analysis.
Becton Dickinson and Company Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Becton Dickinson and Company; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Becton Dickinson and Company’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Becton Dickinson and Company (United States)
Becton Dickinson and Company is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on BCAL Diagnostics Ltd
Frequently asked questions
What is Becton Dickinson and Company?
What is the latest Becton Dickinson and Company price?
Is Becton Dickinson and Company in an uptrend?
How volatile is Becton Dickinson and Company?
What factors affect Becton Dickinson and Company?
Which trading strategies trade Becton Dickinson and Company?
How are Becton Dickinson and Company returns analysed?
Where can I download free Becton Dickinson and Company historical data?
Free Becton Dickinson and Company historical data (last 10 years)
Browse or instantly download the last 10 years of Becton Dickinson and Company daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.BDX.NYSE&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 212.78 |
| 2026-11-19 | 212.68 |
| 2026-11-18 | 216.08 |
| 2026-11-17 | 215.42 |
| 2026-11-16 | 216.47 |
| 2026-11-13 | 218.03 |
| 2026-11-12 | 215.71 |
| 2026-11-11 | 214.52 |
| 2026-11-10 | 212.61 |
| 2026-11-09 | 215.25 |
About this stock
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.